LACTOLOGY FOUNDATION

Tilactase (Lactase) (ATC A09AA04): Toxicological and Lactation Monograph

ATC Class and General Pharmacology

Tilactase, also known as lactase, is classified as ATC A09AA04 in the World Health Organization Anatomical Therapeutic Chemical classification system:

• A — Alimentary Tract and Metabolism
• A09 — Digestives, including enzymes
• A09AA — Enzyme preparations
• A09AA04 — Tilactase

The ATC classification places tilactase among enzyme preparations used for digestive disorders. Tilactase is the international nonproprietary designation associated with lactase preparations, which are used to assist digestion of lactose, the principal carbohydrate in mammalian milk and dairy-containing foods.atcddd.fhi+1

Lactase is a beta-galactosidase enzyme. Its physiological role is to hydrolyse lactose into the monosaccharides glucose and galactose, which can then be absorbed through the intestinal mucosa. In humans, endogenous lactase is normally expressed at the brush border of small-intestinal enterocytes, particularly in the proximal small bowel.

Oral tilactase is used as enzyme supplementation in individuals with lactose maldigestion or lactose intolerance. It may be administered immediately before or together with lactose-containing foods, added directly to milk, or used in formulations intended to pre-hydrolyse lactose before consumption. The clinical objective is reduction of lactose-related gastrointestinal symptoms, including abdominal bloating, borborygmi, cramping, flatulence, urgency, and osmotic diarrhoea.

Pharmacological activity is local to the gastrointestinal tract or to the food or milk product to which the enzyme has been added. Tilactase is not intended to be absorbed systemically or to exert systemic pharmacodynamic activity. It is a proteinaceous enzyme that functions by acting on lactose in the intestinal lumen or in the treated food product.

The product category includes tablets, capsules, chewable formulations, drops, powders, and preparations that can be added to milk. Product quality and composition vary. Some products contain only lactase, whereas others contain sweeteners, flavourings, sugars, preservatives, vitamins, probiotics, additional digestive enzymes, or food-supplement ingredients. These differences are important when assessing toxicological and lactation safety.

Toxicological Profile

At normal oral doses, tilactase has a favourable toxicological profile. Because it acts locally on lactose and is expected to undergo gastrointestinal digestion as a protein, clinically relevant systemic exposure is not expected. Reported unwanted effects are uncommon and are generally mild when they occur.

Possible adverse effects include:

• Mild abdominal discomfort, nausea, bloating, altered stool frequency, or diarrhoea.
• Symptoms caused by continued ingestion of lactose beyond the individual’s digestive capacity, which may be mistaken for an adverse reaction to the lactase product.
• Intolerance to excipients, including sweeteners, flavourings, preservatives, sugar alcohols, colourants, or other additives.
• Product-specific effects from additional active ingredients in combination preparations.

The principal clinically relevant adverse effect is hypersensitivity. Although rare, IgE-mediated allergy to supplemental oral lactase has been documented, including anaphylaxis associated with synthetic lactase enzyme exposure. A more recent review describes lactase allergy as sparsely reported but confirms that prior anaphylaxis cases exist.pmc.ncbi.nlm.nih+1

Possible signs of an allergic reaction include urticaria, pruritus, facial or lip swelling, throat tightness, wheeze, dyspnoea, dizziness, vomiting, or collapse. Individuals with a known allergy to lactase preparations, enzyme products, fungal or microbial fermentation products, or a specific formulation component should not use the product without specialist assessment.

Many commercial lactase products are manufactured using microbial fermentation. The enzyme source and degree of purification vary by product, and this may be relevant for people with a history of sensitivity to moulds, microbial enzymes, or occupational enzyme-related allergy. A patient who develops immediate symptoms after use should discontinue the product and seek medical evaluation.

Toxicological concerns can also arise from unsuitable use. Tilactase is not a treatment for cow’s milk protein allergy, inflammatory bowel disease, coeliac disease, gastrointestinal infection, pancreatic disease, or unexplained chronic diarrhoea. It should not be used as a reason to delay diagnostic evaluation when symptoms are persistent, severe, associated with weight loss, gastrointestinal bleeding, dehydration, nocturnal symptoms, fever, or impaired growth.

Lactation Pharmacology and Infant Exposure

There are limited direct studies measuring lactase concentrations in human milk after maternal oral tilactase use. However, the pharmacokinetic and biochemical properties of lactase strongly predict negligible transfer into breast milk.

Tilactase is a large proteinaceous enzyme intended to act within the maternal gastrointestinal tract. It is susceptible to denaturation and digestion in the stomach and intestine, and intact absorption into the maternal circulation is expected to be minimal. Consequently, the quantity available in maternal plasma for passage into milk should be negligible.

If a very small amount of enzyme-derived material reached human milk, it would be expected to undergo digestion in the infant gastrointestinal tract. Clinically significant systemic exposure of the breastfed infant is therefore biologically implausible. An independent lactation reference similarly concludes that, although direct milk-excretion data were not identified, the protein nature and high molecular weight of lactase make excretion into milk highly unlikely.e-lactation

Maternal use of tilactase is not expected to alter milk production, prolactin secretion, milk fat content, milk protein content, or the normal lactose concentration of human milk. Importantly, the lactose content of breast milk is largely independent of maternal dietary lactose intake and varies only minimally. Therefore, a mother avoiding dairy foods or taking oral lactase does not make her breast milk lactose-free.breastfeedingnetwork

This distinction has practical clinical importance. Maternal lactase supplementation treats maternal lactose digestion; it does not treat an infant’s lactose intolerance, congenital lactase deficiency, secondary lactose malabsorption, or suspected cow’s milk protein allergy. Likewise, maternal avoidance of dairy because of lactose intolerance should not be presented as an intervention that reduces the physiological lactose content of human milk.

Some lactase preparations are used directly in expressed breast milk or infant feeds, rather than being taken by the mother. That use represents direct infant exposure and should be evaluated under paediatric guidance. Certain lactase products are specifically designed to be added to expressed milk and allowed time to hydrolyse lactose before feeding. This is pharmacologically and clinically distinct from maternal oral use during lactation.breastfeeding

Lactological Safety Assessment and Clinical Recommendations

Oral tilactase used by a breastfeeding mother is generally considered compatible with breastfeeding. The enzyme acts locally in the maternal gastrointestinal tract, is unlikely to be absorbed intact into maternal circulation, and is therefore unlikely to reach human milk in clinically meaningful quantities.e-lactation

No interruption of breastfeeding, temporary cessation, pumping and discarding, or change in infant feeding is routinely required because of maternal use of a conventional lactase-only product. Lactase products are also described in clinical drug-information sources as usable during breastfeeding, although this conclusion is based largely on pharmacological reasoning rather than robust milk-concentration studies.rxlist+1

Clinical recommendations

• A lactating mother with lactose intolerance may use a conventional single-ingredient lactase product when needed to improve tolerance of lactose-containing foods.
• Choose a clearly labelled and preferably regulated product with known enzyme activity and minimal unnecessary additives.
• Take the product according to manufacturer instructions, usually with lactose-containing food or drink, since its benefit depends on contact with dietary lactose.
• Do not discontinue breastfeeding because of maternal lactose intolerance or maternal tilactase use.
• Explain that maternal dietary lactose restriction and maternal lactase use do not reduce the lactose naturally present in breast milk.breastfeedingnetwork
• Review the complete formulation before use, especially chewable tablets, syrups, flavoured products, and dietary supplements that may contain sugars, sugar alcohols, aspartame, alcohol, herbal ingredients, probiotics, or other digestive enzymes.
• Avoid a product in women with a known lactase-enzyme allergy or a previous immediate reaction to the same product. Suspected allergic reactions require prompt discontinuation and medical evaluation.
• Seek medical assessment for persistent or severe maternal gastrointestinal symptoms, especially weight loss, anaemia, rectal bleeding, nocturnal diarrhoea, recurrent vomiting, fever, dehydration, or symptoms not reliably linked to lactose ingestion.
• Seek paediatric evaluation rather than self-treating through maternal diet or medication if the breastfed infant has poor growth, persistent diarrhoea, vomiting, blood or mucus in stools, eczema with gastrointestinal symptoms, or suspected cow’s milk protein allergy.

Infant monitoring

Routine additional monitoring of a healthy full-term breastfed infant is not required when the mother uses oral tilactase. Infant exposure through milk is not expected to be clinically relevant.

As a general precaution, clinical review is appropriate if an infant develops persistent vomiting, diarrhoea, feeding difficulty, rash, wheeze, blood in the stool, excessive irritability, or poor weight gain. These findings should not be attributed automatically to maternal lactase use; they are more likely to require assessment for independent infant gastrointestinal, infectious, feeding, or allergic conditions.

If lactase is added directly to expressed breast milk or infant formula, the infant is being exposed to the enzyme and to a partially hydrolysed lactose feed. Such use should follow product instructions and paediatric or lactation-professional advice, particularly for preterm infants, infants with metabolic disease, or infants with complex gastrointestinal symptoms.

Overall conclusion

Tilactase (lactase; A09AA04) is a locally acting beta-galactosidase enzyme used to facilitate lactose digestion. Following maternal oral administration, intact systemic absorption and transfer into breast milk are expected to be negligible. Consequently, clinically meaningful infant exposure through human milk is unlikely.atcddd.fhi+1

Breastfeeding can generally continue without restriction when a mother uses a conventional lactase-only preparation. The main precautions concern rare enzyme hypersensitivity, product-specific excipients, combination formulations, and the need to investigate persistent maternal or infant gastrointestinal symptoms rather than treating them empirically. Rare but documented allergic reactions, including anaphylaxis, mean that mothers with suspected lactase allergy should discontinue the product and receive clinical assessment.pmc.ncbi.nlm.nih+1